This ETF is one of the options available for investors looking to access the pharmaceutical industry, a sub-sector of health care that has the potential to perform well during periods of consolidation and that may be appealing as a source of capital appreciation over the long run. Given the targeted focus of IHE, this ETF probably isn't that useful as a core holding in a long-term portfolio; it may, however, be appealing to those looking to apply a tactical tilt towards pharma or implement a sector rotation strategy. IHE is somewhat concentrated, with a relatively shallow basket of holdings and significant weightings afforded to the larger companies in the underlying index. Other options for exposure to pharmaceutical firms include PPH (which is extremely concentrated) and XPH, which is linked to an equal-weighted index and therefore may offer better balance. There is also the "Dynamic" PJP, a more expensive option that may be attractive for those who believe the quant-based methodology adds value.